NCT00443690View on ClinicalTrials.gov

Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy

PHASE3CompletedINTERVENTIONAL

Enrollment

480

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

Heart Failure, Congestive

Interventions

DRUG

rolofylline

rolofylline 30 mg IV QD; 3 days

DRUG

Comparator: Placebo (unspecified)

rolofylline Pbo 30 mg IV QD; 3 days

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00443690 - Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy | Biotech Hunter | Biotech Hunter